TABLE 1.
HO | CO | Total | |
---|---|---|---|
All | 161 (67.36%) | 78 (32.64%) | 239 (100%) |
Sex | |||
Male | 101 (62.73%) | 57 (73.08%) | 158 (66.11%) |
Female | 60 (37.27%) | 21 (26.92%) | 81 (33.89%) |
Age | |||
Children (0–6 years) | 14 (8.70%) | 1 (1.28%) | 15 (6.28%) |
Early youth (7–17 years) | 1 (.62%) | 0 (.00%) | 1 (.42%) |
Youth (18–40 years) | 15 (9.32%) | 9 (11.54%) | 24 (10.04%) |
Middle (41–65 years) | 74 (45.96%) | 44 (56.41%) | 118 (49.37%) |
Aged (>65 years) | 57 (35.40%) | 24 (30.77%) | 81 (33.89%) |
Districts | |||
East China | 74 (45.96%) | 35 (44.87%) | 109 (45.61%) |
South China | 27 (16.77%) | 18 (23.08%) | 45 (18.83%) |
Southwest China | 25 (15.53%) | 6 (7.69%) | 31 (12.97%) |
Northeast China | 23 (14.29%) | 6 (7.69%) | 29 (12.13%) |
North China | 7 (4.35%) | 6 (7.69%) | 13 (5.44%) |
Central China | 5 (3.11%) | 4 (5.13%) | 9 (3.77%) |
Northwest China | 0 (.00%) | 3 (3.85%) | 3 (1.26%) |
Sequence type | |||
ST11 | 56 (34.78%) | 9 (11.54%) | 65 (27.20%) |
ST23 | 10 (6.21%) | 11 (14.10%) | 21 (8.79%) |
ST65 | 9 (5.59%) | 3 (3.85%) | 12 (5.02%) |
ST15 | 7 (4.35%) | 3 (3.85%) | 10 (4.18%) |
ST29 | 6 (3.73%) | 3 (3.85%) | 9 (3.77%) |
Other STs | 73 (45.34%) | 49 (62.82%) | 122 (51.05%) |
Capsular (K) serotype | |||
K64 | 44 (27.33%) | 9 (11.54%) | 53 (22.18%) |
K1 | 12 (7.45%) | 15 (19.23%) | 27 (11.30%) |
K2 | 18 (11.18%) | 9 (11.54%) | 27 (11.30%) |
K47 | 12 (7.45%) | 2 (2.56%) | 14 (5.86%) |
K54 | 7 (4.35%) | 4 (5.13%) | 11 (4.60%) |
Other Ks | 68 (42.24%) | 39 (50.00%) | 107 (44.77%) |
Lipopolysaccharide (O) serotype | |||
O1v2 | 45 (27.95%) | 31 (39.74%) | 76 (31.80%) |
O2v1 | 44 (27.33%) | 9 (11.54%) | 53 (22.18%) |
O1v1 | 25 (15.53%) | 18 (23.08%) | 43 (17.99%) |
O2v2 | 12 (7.45%) | 6 (7.69%) | 18 (7.53%) |
OL101 | 13 (8.07%) | 4 (5.13%) | 17 (7.11%) |
Other Os | 22 (13.66%) | 10 (12.82%) | 32 (13.39%) |